Keywords: significant, bmd, rise, seen, fosamax, longest, randomized
Significant BMD rise seen with Fosamax
Article | 29 March 2004
In the longest randomized clinical trial in osteoporosis, researchers found that post-menopausal women taking Merck & Co's Fosamax (alendronate) experience significant ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
